Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Mouse Tumor Models for Advanced Cancer Immunotherapy

Modeling the Tumor Microenvironment and Cancer Immunotherapy in Next-Generation Humanized Mice

Mouse models in oncoimmunology

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Trials, Tribulations, and Trends in Tumor Modeling in Mice

Humanized mouse models for immuno-oncology research

Transgenic Mouse Models in Cancer Research

Humanized Mouse Models for Immuno-oncology Drug Discovery

Experimental mouse models for translational human cancer research

Mouse Models for Immunotherapy in Hepatocellular Carcinoma

Humanized Rodent Models for Cancer Research

Humanized mouse models: A valuable platform for preclinical evaluation of human cancer

Development of humanized mouse with patient‐derived xenografts for cancer immunotherapy studies: A comprehensive review

Mouse Models for Immune Checkpoint Blockade Therapeutic Research in Oral Cancer

Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells

Mouse models of breast cancer in preclinical research

Technical considerations and strategies for generating and optimizing humanized mouse tumor models in immuno-oncology research

Animal models for modeling pancreatic cancer and novel drug discovery

Human Immune System Mice With Autologous Tumor for Modeling Cancer Immunotherapies

In vivo mouse models for adult brain tumors: Exploring tumorigenesis and advancing immunotherapy development

Humanized Germ-Free Mice for Investigating the Intervention Effect of Commensal Microbiome on Cancer Immunotherapy